ライフサイエンスコーパス: donor-specific tolerance

1 ponse, immunosuppressed T cell response, and donor specific tolerance.

2 o resulted in a state of mixed chimerism and donor specific tolerance.

3 rom rejection, and subsequently demonstrated donor-specific tolerance.

4 stem cell transplantation (HSCT) can lead to donor-specific tolerance.

5 promote long-term graft survival and induce donor-specific tolerance.

6 tablishment of long-term mixed chimerism and donor-specific tolerance.

7 sible therapy to prevent TVS is induction of donor-specific tolerance.

8 indicated that the recipients had developed donor-specific tolerance.

9 transient anti-LFA-1 monotherapy resulted in donor-specific tolerance.

10 row transplantation model in order to induce donor-specific tolerance.

11 e) results in mixed xenogeneic chimerism and donor-specific tolerance.

12 h to achieve mixed bone marrow chimerism and donor-specific tolerance.

13 r anergy, is the major mechanism maintaining donor-specific tolerance.

14 ing that their adoptive transfer can promote donor-specific tolerance.

15 emonstrated to effectively induce allogeneic donor-specific tolerance.

16 e maintenance immunosuppression or to induce donor-specific tolerance.

17 afts was used to test for the development of donor-specific tolerance.

18 g mice, although the animals did not develop donor-specific tolerance.

19 (MR1) and human CTLA4Ig were sued to induce donor-specific tolerance.

20 ression for many years, suggesting permanent donor-specific tolerance.

21 soform by mAb (anti-CD45RB) reliably induces donor-specific tolerance.

22 encoded allogeneic MHC class I Ag results in donor-specific tolerance.

23 thout immunosuppression to assess for robust donor-specific tolerance.

24 CD28 stimulation-based strategies to induce donor-specific tolerance.

25 S/BM150/sirolimus protocol showed indefinite donor-specific tolerance.

26 performed previously in adult mice to induce donor-specific tolerance across allogeneic and xenogenei

27 induction of mixed allogeneic chimerism and donor-specific tolerance across full MHC barriers.

28 h induction of permanent mixed chimerism and donor-specific tolerance across fully MHC-mismatched all

29 al antibody and CsA resulted in induction of donor-specific tolerance across the MHC barrier without

30 The induction of bone marrow chimerism and donor-specific tolerance after nonlethal conditioning mi

31 x 10(6)) from CD4 mAb-treated rats conferred donor-specific tolerance after transfer into new sets of

32 ccepted a heart allotransplant and displayed donor-specific tolerance also accepted skin grafts from

33 this agent before transplantation can induce donor-specific tolerance and "split tolerance" to renal

34 sess efficacy of immunodepletion and confirm donor-specific tolerance and chimerism.

35 as long been known to be capable of inducing donor-specific tolerance and hence permitting allograft

36 Donor-specific tolerance and immunocompetence of long-te

37 Donor-specific tolerance and immunocompetence were deter

38 t rather spontaneously develop transferable, donor-specific tolerance and linked suppression in vivo.

39 el nonmyeloablative approach that results in donor-specific tolerance and mixed allogeneic chimerism.

40 before transplantation resulted in long-term donor-specific tolerance and prevented GVHD.

41 The chimeric NOD recipients showed donor-specific tolerance and reversal of insulitis.

42 ALS, BM, and sirolimus results in a state of donor-specific tolerance, and multilineage chimerism evo

43 5RB to produce indefinite graft survival and donor-specific tolerance, and this effect is accomplishe

44 Mixed chimerism and donor-specific tolerance are achieved in mice receiving

45 rt illustrate that established mechanisms of donor-specific tolerance are strained during potent immu

46 6 (B6, H-2(b)) heart transplants resulted in donor-specific tolerance associated with long-term survi

47 ed lymphocyte reaction and ELISPOT) revealed donor-specific tolerance before and after transplantatio

48 e approach that achieves mixed chimerism and donor-specific tolerance but has been limited by minimal

49 ion (IUHCTx) is a promising method to induce donor-specific tolerance but the mechanisms of antigen p

50 e discuss new approaches to the induction of donor-specific tolerance by induction of molecular chime

51 ivors were analyzed for in vitro evidence of donor-specific tolerance by mixed leukocyte reaction (ML

52 Donor-specific tolerance can be achieved in a subset of

53 Durable engraftment and donor-specific tolerance can be achieved with mPBMC in n

54 table mixed hematopoietic cell chimerism and donor-specific tolerance can be established in miniature

55 Donor-specific tolerance can be induced across a discord

56 Xenogeneic donor-specific tolerance can be induced by transplanting

57 e have recently demonstrated that xenogeneic donor-specific tolerance can be induced by transplanting

58 that xenogeneic bone marrow engraftment and donor-specific tolerance can be induced in mice receivin

59 IS-free donor-specific tolerance can be successfully induced wit

60 ite survival of LBNF1 cardiac allografts; 2) donor-specific tolerance can be then transferred by sple

61 This donor-specific tolerance can then be transferred into a

62 Donor-specific tolerance could be adoptively transferred

63 rpose of this study was to determine whether donor-specific tolerance could be detected in T cells wi

64 Over time, a state of donor-specific tolerance develops in which recipients ar

65 Donor-specific tolerance did not develop clinically or i

66 Long-term chimeras developed donor-specific tolerance (donor skin graft survival of m

67 Donor-specific tolerance (DST) is induced after allogene

68 us to achieve mixed allogeneic chimerism and donor-specific tolerance (DST).

69 between some strains of rodents can lead to donor-specific tolerance either spontaneously or after a

70 Chimeras exhibit robust donor-specific tolerance, evidenced by acceptance of ful

71 the future be used as a method of increasing donor-specific tolerance following IUHCT.

72 ssociation between hemopoietic chimerism and donor-specific tolerance for allografts has been recogni

73 le for up to 2 years and was associated with donor-specific tolerance for renal transplantation.

74 fter bone marrow transplantation may provide donor-specific tolerance for solid organ allografts.

75 In animal models, mixed chimerism confers donor-specific tolerance for solid-organ and cellular gr

76 Furthermore, donor-specific tolerance from anti-LFA-1-treated animals

77 nt) resulted in long term graft survival and donor-specific tolerance in 30 to 50% of the recipients.

78 term pancreatic islet allograft survival and donor-specific tolerance in a mouse model.

79 ally applicable 35-day protocol that induces donor-specific tolerance in a rat hindlimb-transplantati

80 of CTLA4Ig induced long-term engraftment and donor-specific tolerance in all three groups of recipien

81 ixed hematopoietic chimerism leads to stable donor-specific tolerance in allogeneic and closely relat

82 tation can be an effective way for inducting donor-specific tolerance in allogeneic recipients.

83 Ab to promote mixed xenogeneic chimerism and donor-specific tolerance in B6 mice receiving anti-CD8,

84 r data suggest that this approach may induce donor-specific tolerance in clinical islet transplantati

85 MLR and skin grafting confirmed donor-specific tolerance in euthymic recipients.

86 ately predict the development or presence of donor-specific tolerance in humans after transplantation

87 macrochimerism is frequently associated with donor-specific tolerance in many experimental animals an

88 t to inhibit T1D development and also induce donor-specific tolerance in NOD recipients.

89 ow chimerism has been demonstrated to confer donor-specific tolerance in nonsensitized recipients, bu

90 This local immunotherapy imparted systemic donor-specific tolerance in otherwise immunocompetent ra

91 f thymus was imperative for the induction of donor-specific tolerance in rat hind-limb composite tiss

92 shown promise as agents capable of inducing donor-specific tolerance in rodents.

93 ell transplantation has been shown to induce donor-specific tolerance in small-animal models.

94 arrow cell (BMC) engraftment, chimerism, and donor-specific tolerance in the absence of the side effe

95 s in in vivo cytotoxicity assays, suggesting donor-specific tolerance in the innate immune cells was

96 istration of CsA and ALS for 21 days induced donor-specific tolerance in the recipients of the rat hi

97 servations are relevant to the mechanisms of donor-specific tolerance in this patient group.

98 te reaction (MLR) and skin grafting assessed donor-specific tolerance in vitro and in vivo, respectiv

99 Mixed lymphocyte reaction for donor-specific tolerance in vitro was tested at day 160

100 r chimerism was established by TDBMT induced donor-specific tolerance in vivo and in vitro.

101 etermine the level of chimerism and possible donor-specific tolerance, in addition to possible GVHD.

102 r understanding of the processes that govern donor-specific tolerance increases, so must our understa

103 Donor-specific tolerance induced by BMC prevented allogr

104 Donor-specific tolerance induced by bone marrow transpla

105 infiltrating host cells, and the spontaneous donor-specific tolerance induced by liver but not heart

106 d the efficacy of CD4-targeted therapy, with donor-specific tolerance induced in approximately 50% of

107 ation to allow permanent mixed chimerism and donor-specific tolerance induction can be overcome by th

108 Therefore, in addition to focusing on donor-specific tolerance induction, strategies aiming at

109 e endogenous superantigens demonstrated that donor-specific tolerance is due mainly to an intrathymic

110 se model of cardiac transplantation in which donor-specific tolerance is induced with costimulation b

111 To examine them for donor-specific tolerance, long-term unresponsive (>120 d

112 oal in transplantation is the achievement of donor-specific tolerance, minimizing the use of immunosu

113 esults in permanent engraftment (>250 d) and donor-specific tolerance not observed previously in this

114 To study the effects of donor-specific tolerance on chronic rejection, we perfor

115 , anti-CD8 mAb administration did not induce donor-specific tolerance or cause nonspecific immune sup

116 Donor-specific tolerance remains a goal in transplantati

117 The induction of donor-specific tolerance remains a major goal in the fie

118 ionally transplanted patients, thus, whether donor-specific tolerance results in improved outcomes re

119 gulated within allografts of mice displaying donor-specific tolerance, that recruitment of Foxp3-expr

120 We developed an efficient donor-specific tolerance therapy that utilizes infusions

121 Donor-specific tolerance through establishing mixed chim

122 m mixed hematopoietic chimerism and systemic donor-specific tolerance through peripheral and central

123 This expansion led to donor-specific tolerance through robust increases in pol

124 ts establish a less toxic method of inducing donor-specific tolerance, thus increasing the potential

125 These data demonstrated that donor-specific tolerance to all components of the VCA ca

126 Permanent donor-specific tolerance to allografts is the goal of tr

127 orm by mAb (anti-CD45RB) effectively induces donor-specific tolerance to allografts.

128 These B6 nu/nu mice maintained donor-specific tolerance to B10.A skin grafts.

129 quences in the alpha1-helical region induces donor-specific tolerance to cardiac allografts in rat re

130 men produces mixed bone marrow chimerism and donor-specific tolerance to cardiac allografts in the ra

131 Donor-specific tolerance to cardiac allografts was induc

132 hown that mixed allogeneic chimerism induces donor-specific tolerance to composite tissue allografts

133 Mixed chimerism induces donor-specific tolerance to composite tissue allotranspl

134 resent a new approach of inducing long-term, donor-specific tolerance to CTAs without recipient preco

135 etic-cell transplantation (IUHCT) can induce donor-specific tolerance to facilitate postnatal transpl

136 chronic immunosuppression, the induction of donor-specific tolerance to intestinal grafts is desirab

137 Mixed chimerism induces donor-specific tolerance to kidney and vascularized comp

138 into a lethally irradiated rat, would confer donor-specific tolerance to lung allografts.

139 Minimization of immunosuppression and donor-specific tolerance to MHC-mismatched organ grafts

140 gulatory cells are required and can transfer donor-specific tolerance to naive recipients.

141 Donor-specific tolerance to NOR islet grafts was induced

142 e development of effective methods to induce donor-specific tolerance to obviate the need for life-lo

143 ecule LFA-1 (CD11a) was sufficient to induce donor-specific tolerance to pancreatic islet allografts.

144 hocyte serum (ALS) intraperitoneally induces donor-specific tolerance to rat cardiac transplants.

145 Donor-specific tolerance to renal allografts in miniatur

146 finite allograft acceptance (>300 days), and donor-specific tolerance to secondary skin grafts.

147 finite allograft acceptance (>350 days), and donor-specific tolerance to secondary skin grafts.

148 antly enhance engraftment of HSCs and induce donor-specific tolerance to skin allografts.

149 exhibited stable multilineage chimerism and donor-specific tolerance to skin grafts and in in vitro

150 exhibited stable multilineage chimerism and donor-specific tolerance to subsequent cardiac allograft

151 amycin and IL-2/Fc fusion protein results in donor-specific tolerance to VCA, but not FTS allografts.

152 ansplantation as part of a regimen to induce donor-specific tolerance to xenogeneic organ grafts.

153 If donor-specific tolerance toward porcine antigens could b

154 haploidentical chimeric mice also displayed donor-specific tolerance upon stimulation in a one-way m

155 in solid organ xenografting may be to induce donor-specific tolerance using bone marrow transplantati

156 The induction of donor specific tolerance via bone marrow chimerism may b

157 w) subpopulation, which are able to transfer donor-specific tolerance via IL-10 and TGF-beta1-depende

158 Donor-specific tolerance was assessed with mixed lymphoc

159 Donor-specific tolerance was confirmed by acceptance of

160 Donor-specific tolerance was tested by skin grafting.

161 Achieving stable and durable donor-specific tolerance, whereby immunosuppression can

162 The ultimate goal is to induce a state of donor-specific tolerance, wherein the recipient will acc

163 an achieve mixed hematopoietic chimerism and donor-specific tolerance without cytoreductive condition

164 patibility complex (MHC) barriers and induce donor-specific tolerance without immunosuppressive thera

165 are accepted across MHC barriers and induce donor-specific tolerance without immunosuppressive thera

166 ty complex (MHC) barriers in mice and induce donor-specific tolerance without requirement for immunos

167 Bone marrow chimerism induces donor-specific tolerance without the requirement for chr

168 pted the postulation that prior induction of donor-specific tolerance would attenuate or abrogate the

169 complete recipient ablation (A-->B) exhibit donor-specific tolerance, yet survival is often limited